Jean‐Frédéric Blanc

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification

Julien Caldéraro, Gabrielle Couchy, Sandrine Imbeaud et al. · Journal of Hepatology · 2017 · 746 citations

Hepatology, Medicine, Histopathology +9

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul et al. · Journal of Clinical Oncology · 2013 · 592 citations · Full text

Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry

Paulette Bioulac‐Sage, Sandra Rebouissou, Cristel G. Thomas et al. · Hepatology · 2007 · 586 citations